Microfluidic approaches for liquid biopsy in glioblastoma: Insights into diagnostic and follow‐up strategies

IF 6.1 2区 医学 Q1 ENGINEERING, BIOMEDICAL
Clara Bayona, Teodora Ranđelović, Claudia Olaizola‐Rodrigo, Ignacio Ochoa
{"title":"Microfluidic approaches for liquid biopsy in glioblastoma: Insights into diagnostic and follow‐up strategies","authors":"Clara Bayona, Teodora Ranđelović, Claudia Olaizola‐Rodrigo, Ignacio Ochoa","doi":"10.1002/btm2.70032","DOIUrl":null,"url":null,"abstract":"Glioblastoma (GBM) is a highly malignant brain tumor with a poor survival prognosis of 12–15 months despite current therapeutic strategies. Diagnosing GBM is challenging, often requiring invasive techniques such as tissue biopsy and imaging methods that can provide inconclusive results. In this regard, liquid biopsy represents a promising alternative, providing tumor‐derived information from less invasive sources such as blood or cerebrospinal fluid. However, the typically low concentrations of these biomarkers pose challenges for traditional detection techniques, limiting their sensitivity and specificity. Recent advances in microfluidics offer a potential solution by enhancing the isolation and detection of tumor‐derived cells and molecules, thus improving their detectability. This review discusses the latest progress in microfluidic‐based liquid biopsy systems for glioblastoma, laying the basis for future diagnostic practices that are less invasive and more accurate. As these technologies evolve, they hold the potential to transform GBM diagnosis and monitoring, ultimately improving patient outcomes.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"76 1","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioengineering & Translational Medicine","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1002/btm2.70032","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Glioblastoma (GBM) is a highly malignant brain tumor with a poor survival prognosis of 12–15 months despite current therapeutic strategies. Diagnosing GBM is challenging, often requiring invasive techniques such as tissue biopsy and imaging methods that can provide inconclusive results. In this regard, liquid biopsy represents a promising alternative, providing tumor‐derived information from less invasive sources such as blood or cerebrospinal fluid. However, the typically low concentrations of these biomarkers pose challenges for traditional detection techniques, limiting their sensitivity and specificity. Recent advances in microfluidics offer a potential solution by enhancing the isolation and detection of tumor‐derived cells and molecules, thus improving their detectability. This review discusses the latest progress in microfluidic‐based liquid biopsy systems for glioblastoma, laying the basis for future diagnostic practices that are less invasive and more accurate. As these technologies evolve, they hold the potential to transform GBM diagnosis and monitoring, ultimately improving patient outcomes.
胶质母细胞瘤液体活检的微流体方法:诊断和随访策略的见解
胶质母细胞瘤(GBM)是一种高度恶性的脑肿瘤,尽管目前的治疗策略,其生存预后很差,只有12-15个月。诊断GBM是具有挑战性的,通常需要侵入性技术,如组织活检和成像方法,可以提供不确定的结果。在这方面,液体活检是一种有希望的替代方法,可以从血液或脑脊液等侵入性较小的来源提供肿瘤来源的信息。然而,这些生物标志物的典型低浓度给传统检测技术带来了挑战,限制了它们的灵敏度和特异性。微流体技术的最新进展提供了一种潜在的解决方案,通过增强对肿瘤来源的细胞和分子的分离和检测,从而提高它们的可检测性。本文综述了基于微流体的胶质母细胞瘤液体活检系统的最新进展,为未来更低侵入性和更准确的诊断实践奠定基础。随着这些技术的发展,它们有可能改变GBM的诊断和监测,最终改善患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Bioengineering & Translational Medicine
Bioengineering & Translational Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
8.40
自引率
4.10%
发文量
150
审稿时长
12 weeks
期刊介绍: Bioengineering & Translational Medicine, an official, peer-reviewed online open-access journal of the American Institute of Chemical Engineers (AIChE) and the Society for Biological Engineering (SBE), focuses on how chemical and biological engineering approaches drive innovative technologies and solutions that impact clinical practice and commercial healthcare products.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信